501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia -- June
7, 2022 -- InvestorsHub NewsWire -- Cannabix Technologies Inc.
(CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
marijuana breathalyzer devices for law enforcement and the
workplace reports that it will attending and presenting its
research: Correlation of
Breath and Blood Cannabis Levels Using Custom-Made Breath Sample
Collection and Analysis Methods at Breath Summit 2022 hosted by the
International Association of Breath Research (IABR) in mid-June
2022. The IABR Breath
Summit is one
the premier events held globally in relation to breath research.
The conference is focused on the latest breakthroughs and emerging
topics in breath chemical analysis, sensor instrumentation and
biomarker detection and identification strategies. The conference
attracts worldwide attendees from multidisciplinary industry and
academic groups.
Cannabix will present its technical
expertise in breath aerosol analysis and recent breath testing
benchmarks with its FAIMS and THC Breath Analyzer technologies for
detection of ?9-tetrahydrocannabinol ("THC"). In addition, Cannabix
will present its results from THC analytes captured in human breath
performed by an independent experimental study. The study showed
excellent correlation between breath samples collected and analyzed
with Cannabix hardware and blood plasma levels of THC (see news
release dated May 9, 2022). The Company's handheld
Breath
Collection Unit and newly developed
laboratory "MS Breath
Sampler" were
used together to provide a new ground-breaking method for portable
drug detection that complements gold-standard mass spectrometry.
The Company has developed a unique breath analysis system, capable
of sampling breath for low volatility analytes, like THC, and can
be completed within seconds, with no sample preparation
needed.
The Company is in discussions with
a range of law enforcement groups who are seeking to test this
hardware and will provide further updates as they become
available.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently
selling commercial breathalyzers. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.